Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mindbio Therapeutics Corp. ( (TSE:MBIO) ) just unveiled an announcement.
MindBio Therapeutics Corp. has issued Restricted Stock Units (RSUs) to its directors, CEO, and staff as compensation, aligning their interests with the company’s goals. This strategic move aims to secure commitment from key personnel as the company progresses into the next stage of clinical trials. Additionally, MindBio has converted CAD$161,000 of payables into shares with two non-related party suppliers, reflecting its innovative approach to financial management. The company is nearing completion of Phase 2B clinical trials and is focused on redefining mental health treatment with scalable and accessible psychedelic-based solutions.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a clinical-stage biopharmaceutical company based in Vancouver, British Columbia, focused on developing novel psychedelic-based medicines for mental health disorders. The company is pioneering the regulated take-home use of psychedelic medicines in clinical trials, aiming to provide safe, effective, and scalable treatments for conditions such as depression and anxiety, with a commitment to improving global mental health outcomes through innovative, evidence-based treatment.
Average Trading Volume: 166,422
Technical Sentiment Signal: Sell
For a thorough assessment of MBIO stock, go to TipRanks’ Stock Analysis page.